Tyrosine Kinase Inhibitors Influence ABCG2 Expression in EGFR-Positive MDCK BCRP Cells via the PI3K/Akt Signaling Pathway

Specific Inhibitors of the Breast Cancer Resistance Protein (BCRP)

(2010) Anne Pick et al.   ChemMedChem

Nilotinib (AMN107, Tasigna ® ) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters

(2009) Amit K. Tiwari et al.   BIOCHEMICAL PHARMACOLOGY

Potent and Selective Inhibitors of Breast Cancer Resistance Protein (ABCG2) Derived from thep-Glycoprotein (ABCB1) Modulator Tariquidar

(2009) Matthias Kühnle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Structure–activity relationships of new inhibitors of breast cancer resistance protein (ABCG2)

(2008) Anne Pick et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

(2008) C Lemos et al.   BRITISH JOURNAL OF CANCER

Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2

(2008) C.-l. Dai et al.   CANCER RESEARCH

The biological properties of cetuximab

(2008) Bruno Vincenzi et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Development of inhibitors of ATP-binding cassette drug transporters – present status and challenges

(2008) Suneet Shukla et al.   Expert Opinion on Drug Metabolism & Toxicology